Comparative Pharmacology
Head-to-head clinical analysis: CARNEXIV versus QUINIDEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARNEXIV versus QUINIDEX.
CARNEXIV vs QUINIDEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CARNEXIV is a formulation of carbidopa and levodopa; levodopa is converted to dopamine in the brain, replenishing depleted dopamine in the striatum, while carbidopa inhibits peripheral decarboxylation of levodopa, increasing central availability.
Class Ia antiarrhythmic agent; blocks sodium channels (fast inward sodium current) and prolongs action potential duration; also has anticholinergic and negative inotropic effects.
1 mg intravenously once daily for 7 days, followed by 1 mg orally once daily for 7 days.
Quinidine sulfate (QUINIDEX): 200-400 mg orally every 6 hours as arrhythmia suppression; maximum 4 g/day. Route: oral, frequency: every 6 hours.
None Documented
None Documented
Terminal elimination half-life is 8-12 hours in patients with normal renal function; prolonged in renal impairment (up to 24-36 hours with CrCl <30 mL/min)
Terminal elimination half-life is 6-8 hours in adults with normal renal and hepatic function; may be prolonged to 10-12 hours in congestive heart failure or hepatic impairment.
Renal (approximately 70% as unchanged drug and metabolites), biliary/fecal (approximately 25-30%)
Renal excretion accounts for approximately 20% unchanged drug; hepatic metabolism (primarily CYP3A4) accounts for 80% with metabolites excreted renally and biliarily; about 5% excreted in feces.
Category C
Category C
Antiarrhythmic Agent
Antiarrhythmic Agent